LABP - Landos announces positive Phase 1 results in inflammatory bowel disease

Landos Biopharma ([[LABP]] -1.1%) has announced that its experimental oral therapy NX-13 met all primary and secondary endpoints in a Phase 1 trial for the treatment of inflammatory bowel disease ("IBD").The randomized, double-blind, placebo-controlled study with single and multiple ascending arms has evaluated the safety, tolerability, and pharmacokinetics of small molecule candidate NX-13.The data has indicated that compared with a placebo, NX-13 was well tolerated with no serious adverse events after the evaluation of multiple doses over one and seven days.The maximum tolerated dose was identified to be 10-times higher than the anticipated therapeutic dose.Following the positive results from the study, the company expects to initiate a Phase 1b trial for NX-13 in patients with ulcerative colitis in 2021.The company that went public in February has shown ‘impressive trial results for its lead program BT-11 for Ulcerative Colitis and Crohn's Disease,’ noted Seeking Alpha contributor Donovan Jones with a bullish rating on

For further details see:

Landos announces positive Phase 1 results in inflammatory bowel disease